Bevacizumab in the treatment of metastatic breast cancer: Friend or foe?

Alberto J. Montero, Mauricio Escobar, Gilberto Lopes, Stefan Glück, Charles Vogel

Research output: Contribution to journalArticle

Abstract

Metastatic breast cancer (MBC) is a major cause of death among women worldwide. Progress has been made in treating MBC with the advent of anti-estrogen therapies, potent cytotoxic agents, and monoclonal antibodies. Bevacizumab is a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), which was approved in 2008 by the US Food and Drug Administration (FDA), for first-line treatment of HER-2 negative MBC in combination with paclitaxel. The FDA then reversed this decision in December 2010 by recommending removal of the MBC indication from bevacizumab, citing primarily safety concerns, and that these risks did not outweigh the ability of bevacizumab to significantly prolong progression-free survival. This decision was unexpected in the oncology community and remains controversial. This review looks at all available phase 3 data with bevacizumab in the MBC setting to determine whether the data support this decision by the FDA, and discusses the future of bevacizumab in breast cancer.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalCurrent Oncology Reports
Volume14
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Breast Neoplasms
United States Food and Drug Administration
Therapeutics
Monoclonal Antibodies
Cytotoxins
Paclitaxel
Vascular Endothelial Growth Factor A
Disease-Free Survival
Bevacizumab
Cause of Death
Estrogens
Safety

Keywords

  • Anti-angiogenesis
  • Bevacizumab
  • Chemotherapy
  • Metastatic breast cancer
  • Randomized control (phase 3) trials
  • Review

ASJC Scopus subject areas

  • Oncology

Cite this

Bevacizumab in the treatment of metastatic breast cancer : Friend or foe? / Montero, Alberto J.; Escobar, Mauricio; Lopes, Gilberto; Glück, Stefan; Vogel, Charles.

In: Current Oncology Reports, Vol. 14, No. 1, 02.2012, p. 1-11.

Research output: Contribution to journalArticle

Montero, AJ, Escobar, M, Lopes, G, Glück, S & Vogel, C 2012, 'Bevacizumab in the treatment of metastatic breast cancer: Friend or foe?', Current Oncology Reports, vol. 14, no. 1, pp. 1-11. https://doi.org/10.1007/s11912-011-0202-z
Montero, Alberto J. ; Escobar, Mauricio ; Lopes, Gilberto ; Glück, Stefan ; Vogel, Charles. / Bevacizumab in the treatment of metastatic breast cancer : Friend or foe?. In: Current Oncology Reports. 2012 ; Vol. 14, No. 1. pp. 1-11.
@article{b5103a6bf4394b9db01a9b920c30d265,
title = "Bevacizumab in the treatment of metastatic breast cancer: Friend or foe?",
abstract = "Metastatic breast cancer (MBC) is a major cause of death among women worldwide. Progress has been made in treating MBC with the advent of anti-estrogen therapies, potent cytotoxic agents, and monoclonal antibodies. Bevacizumab is a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), which was approved in 2008 by the US Food and Drug Administration (FDA), for first-line treatment of HER-2 negative MBC in combination with paclitaxel. The FDA then reversed this decision in December 2010 by recommending removal of the MBC indication from bevacizumab, citing primarily safety concerns, and that these risks did not outweigh the ability of bevacizumab to significantly prolong progression-free survival. This decision was unexpected in the oncology community and remains controversial. This review looks at all available phase 3 data with bevacizumab in the MBC setting to determine whether the data support this decision by the FDA, and discusses the future of bevacizumab in breast cancer.",
keywords = "Anti-angiogenesis, Bevacizumab, Chemotherapy, Metastatic breast cancer, Randomized control (phase 3) trials, Review",
author = "Montero, {Alberto J.} and Mauricio Escobar and Gilberto Lopes and Stefan Gl{\"u}ck and Charles Vogel",
year = "2012",
month = "2",
doi = "10.1007/s11912-011-0202-z",
language = "English (US)",
volume = "14",
pages = "1--11",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Bevacizumab in the treatment of metastatic breast cancer

T2 - Friend or foe?

AU - Montero, Alberto J.

AU - Escobar, Mauricio

AU - Lopes, Gilberto

AU - Glück, Stefan

AU - Vogel, Charles

PY - 2012/2

Y1 - 2012/2

N2 - Metastatic breast cancer (MBC) is a major cause of death among women worldwide. Progress has been made in treating MBC with the advent of anti-estrogen therapies, potent cytotoxic agents, and monoclonal antibodies. Bevacizumab is a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), which was approved in 2008 by the US Food and Drug Administration (FDA), for first-line treatment of HER-2 negative MBC in combination with paclitaxel. The FDA then reversed this decision in December 2010 by recommending removal of the MBC indication from bevacizumab, citing primarily safety concerns, and that these risks did not outweigh the ability of bevacizumab to significantly prolong progression-free survival. This decision was unexpected in the oncology community and remains controversial. This review looks at all available phase 3 data with bevacizumab in the MBC setting to determine whether the data support this decision by the FDA, and discusses the future of bevacizumab in breast cancer.

AB - Metastatic breast cancer (MBC) is a major cause of death among women worldwide. Progress has been made in treating MBC with the advent of anti-estrogen therapies, potent cytotoxic agents, and monoclonal antibodies. Bevacizumab is a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), which was approved in 2008 by the US Food and Drug Administration (FDA), for first-line treatment of HER-2 negative MBC in combination with paclitaxel. The FDA then reversed this decision in December 2010 by recommending removal of the MBC indication from bevacizumab, citing primarily safety concerns, and that these risks did not outweigh the ability of bevacizumab to significantly prolong progression-free survival. This decision was unexpected in the oncology community and remains controversial. This review looks at all available phase 3 data with bevacizumab in the MBC setting to determine whether the data support this decision by the FDA, and discusses the future of bevacizumab in breast cancer.

KW - Anti-angiogenesis

KW - Bevacizumab

KW - Chemotherapy

KW - Metastatic breast cancer

KW - Randomized control (phase 3) trials

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84857626952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857626952&partnerID=8YFLogxK

U2 - 10.1007/s11912-011-0202-z

DO - 10.1007/s11912-011-0202-z

M3 - Article

C2 - 22012632

AN - SCOPUS:84857626952

VL - 14

SP - 1

EP - 11

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 1

ER -